Quetiapine Augmentation in Severe Obsessive Compulsive Disorder

AstraZeneca44 enrolled

Overview

The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Obsessive Compulsive Disorder

Interventions

quetiapine fumarateDRUG

SSRI/ClomipramineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at least 12 weeks of treatment with SSRI or clomipramine Exclusion Criteria: * Substance abuse or dependence, female patients who are pregnant, lactating or at risk of pregnancy, known intolerance or lack of response to quetiapine, use of antihypertensive medication with changing doses

Locations (2)

Research Site

Freiburg im Breisgau, Germany

Research Site

Lübeck, Germany

Outcomes

Primary Outcomes

Absolute change of OCD symptoms from baseline to endpoint on the total Y-BOCS score.

Secondary Outcomes

Change of comorbid psychiatric symptoms and measures of quality of life from baseline to endpoint documented by different scales.

Evaluation of the safety and tolerability profile of quetiapine compared to placebo added to a baseline medication of SSRI/clomipramine.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.